Youcare Pharmaceutical (SH:688658) Xin Lang Cai Jing·2025-11-20 03:39Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a significant increase in its stock price, with a rise of 5.34% to 21.89 yuan per share, and a total market capitalization of 9.85 billion yuan [1] - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, indicating strong growth potential [1] Group 2 - From the perspective of fund holdings, Yuyuan Pharmaceutical is a significant position in the Huashan Fund, specifically in the Huashan CSI 1000 Index Enhanced A fund, which held 10,500 shares, accounting for 0.4% of the fund's net value [2] - The Huashan CSI 1000 Index Enhanced A fund has a total scale of 45.938 million yuan and has achieved a year-to-date return of 24.74%, ranking 2011 out of 4208 in its category [2] - The fund manager, Zhang Xu, has a tenure of 5 years and 188 days, with the best fund return during this period being 142.52% [3]